← The patent line

Hexaminolevulinate Hydrochloride

Sold as CYSVIEW KIT · given by intravesical

Ten years or more until it comes off patent
11.4 yr
Until anyone may copy it
Protection runs to 2038-01-04
6
Trials running now
32 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Photocure Asa
Approval holder
the only company permitted to sell it today
2038-01
Last patent expires
latest patent filed against this product
none listed
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

Bladder CancerCervical Intraepithelial NeoplasiaColorectal Cancer
03

Who is paying for the research

Photocure
Company
16
Joint Authority for Päijät-Häme So
University or hospital
2
GE Healthcare
Company
2

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07669363Phase 22026 · 230 people · not yet recruiting
Hexaminolevulinate Photodynamic Therapy (HAL

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line